Good day, ladies and gentlemen, and welcome to Repligen Corporation’s Year-End and Fourth Quarter of 2018 Earnings Conference Call. My name is Carrie and I will be your coordinator. All participants will be in listen-only mode. [Operator Instructions] Please note, this event is being recorded. Please also note, that there will be a question-and-answer period following the company’s formal remarks. In order to accommodate all individuals who wish to ask questions, there will be a limit of three questions at a time. I would now like to turn the call over to your host for today’s call, Sondra Newman, Senior Director of Investor Relations for Repligen.

Thank you. Good morning. On today’s call we’re reporting on financial results for the fourth quarter and fiscal year 2018 and we’ll provide financial guidance for the year 2019. Repligen President and CEO, Tony Hunt, will cover our business highlights and progress; and our CFO, Jon Snodgres, will provide a financial report. As a reminder, the forward-looking statements that we make during this call including statements regarding our business goals and expectations for the financial performance of the company are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning risk factors is included in our annual report on Form 10-K, the current report on Form 8-K, which we filed today, and other filings that we make with the Securities and Exchange Commission. Today’s comments reflect management’s current views, which could change as a result of new information, future events or otherwise. The company does not obligate or commit itself to update forward-looking statements, except as required by law. During this call, we are providing non-GAAP results and guidance. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this morning, which is posted to Repligen’s website and on sec.gov. The non-GAAP figures in today’s report include, revenue growth at constant currency, gross profit and gross margin, operating expenses and income tax expense, operating income and operating margin, net income, earnings per share, EBITDA and adjusted EBITDA. While these adjusted financial measures should not be viewed as an alternative to GAAP, the company believes that the non-GAAP measures better enable investors to benchmark Repligen’s current results against historical performance and the performance of peers and to evaluate investment opportunities. I’ll turn the call over to Tony Hunt now.

Thank you, Sondra. Good morning, everyone and welcome to our 2018 year-end update. We are delighted with the way we closed out the year with organic growth for the quarter coming in at 25% and for the year at 17%. This above average industry growth was fueled by strong execution by the Repligen team, as we launched new disruptive technologies, supported our customers in the field and scale their operations to keep up with demand. By the impact of a broader and deeper filtration and chromatography portfolio that is delivering flexible high impact solutions to our customers. And finally by the underlying strength of the overall bioprocessing market where there has been a clear increase in the number of drugs coming through the clinical pipeline, which has resulted in investments in capacity expansion and adoption of single-use solutions and outsourcing to CDMOs. We believe we are well positioned to gain further market share, as the industry continues to pivot towards flexible solutions and continuous processing to manufacture the growing number of biological drugs including promising new entrance in gene therapy. Before jumping into the quarter, I want to highlight some of the key accomplishments in 2018. Starting with Spectrum. We focused on three main goals; number one, we wanted to complete the commercial integration. We faced this in over the first half of 2018 creating one sales force focused on filtration and chromatography products. Number two, we wanted to achieve revenue synergies through cross-selling, new product introductions and regional execution. We delivered over $4 million in revenue synergies in 2018 with our flat sheet cassette business benefiting the most and Asia delivering a very strong year through their cross-selling efforts. And finally, number three, we wanted to focus on optimizing operations. Our East Coast and West Coast operations team work…

Thank you, Tony and good morning everyone. Today, we are reporting our financial results for the fourth quarter and full year 2018 as well as providing our financial guidance for the year 2019. Unless otherwise mentioned all financial measures discussed reflect non-GAAP measures. As you’ve seen in our press release this morning, we delivered strong financial performance for both the fourth quarter and full year 2018. We had a record quarter and year with revenues of $51.9 million for Q4 and $194 million for the full year. Organic revenue grew in the fourth quarter by 25%, with adjusted operating income up 31% year-over-year. For full year 2018, our organic revenue grew by 17% with adjusted operating income up 25%. Of our 37% reported revenue growth for the year, 20% was attributed to our 2017 acquisition of Spectrum and we saw less than a 0.5% of tailwind from foreign exchange. Operationally, we continue to make disciplined investments from increased R&D spend to bring new products to market, to effective capital deployment, to increase capacity and bring new facilities online, including the associated systems to support our larger rapidly growing organization. Now to provide more color on our overall financial performance. As Tony mentioned earlier, our direct to customer filtration and chromatography franchises continued to perform well. Our direct products represented approximately 79% of the company’s total revenue in the fourth quarter and about 72% for the full year. Direct revenue growth during the fourth quarter was strongest in Asia and North America, up over 47% and 38% respectively. For the full year on a pro forma basis, all three of our regions grew north of 25%. For the full year of 2018, direct products in Asia, Europe and North America accounted for approximately 16%, 29% and 55% of sales respectively. Now…

We will now begin the question-and-answer session. [Operator Instructions] The first question will come from Tycho Peterson of JPMorgan. Please go ahead.

Hi, good morning guys. This is Julia on for Tycho today. So to start off maybe regarding protein, you said, your 2019 outlook is slightly down 5%. Could you maybe breakdown the moving pieces between the GE transition in-house versus the growth factor, which I think the other third of the protein business. And just regarding the fee transition, is that just them moving in ahead of the contract exploration at year end? Or does that sort of imply a smaller headwind as we look to 2020?

Sure. On the GE – well on the proteins front in general, we’ve now had three years in a row at the proteins business has been essentially flat, right? So when you look at – when we look at 2019, we’re expecting a strong first half of the year for proteins and just like 2018, we expect the second half of the year to be lighter. When you look at the difference between ligands and growth factors, I think you’ll see both ligands and growth factors growing going quite strongly in the first half of the year. We expect growth factors to have some reasonable growth in the year. Ligands will be expect within that portfolio to be down that’s what we’ve seen over the last couple of years. We don’t think 2019 is going to be any different. GE, clearly, will transition to their manufacturing by the end of the year. And then in 2020, obviously start to move whatever percent of manufacturing that they want to move across into their facility. But from 2020 on we expect at least 50% of their volume on a go-forward basis.

Okay. That’s helpful. And then on the filtration side, obviously you’re expecting TangenX and TFF to both ramp this year. So how much revenue expectation contribution do you expect exactly? And besides the commercial focus, obviously what are – are there are any other sort of key drivers for the products to ramp?

Yes. I think, the real way to look at it as the total filtration portfolio. If you look at ATF, just a tremendous year, last year, Spectrum had a great year. The Tangenx flat sheet cassette business had a great year. We’re now moving into 2019. As I said, in my remarks, we had a very strong start to the year in terms of the order load. We have some great products that are coming through that I think will further stimulate demand for our filtration portfolio, whether it’s the ATF controllers, whether it’s the single-use ATF one products that will launch for the smaller scale customers to the TFDF technology that we will have basically bridging between a perfusion and clarification. So we’re excited about that. And then on top of that, we’re really focusing on building out our systems team. We brought people on board in Q4, where expecting to launch a series of TFF systems by second half of this year. That again, will be a stimulus for the overall filtration business.

Got it. And lastly for me, regarding capacity, could you maybe give us an update on your current capacity utilization in light of all the growth investment, how would you expect it to ramp and how much further investment are you expecting to get it to the ideal lead time that you’re targeting? And in light of that, how should we think about the path to growth margin expansion beyond 2019?

Yes. So let me – I’ll handle the – I’ll go through the capacity questions. I’ll let Jon handled the gross margin piece. But in general, we’ve been really diligent about investment in capacity over the last couple of years. If you go back a few years ago, every time, we see a – we make a move in terms of building out our commercial organization, it’s usually takes about six months. And then we see an uptick in demand. That’s exactly what we saw in 2018 as we integrated the two commercial teams. Knowing that what was coming, we’ve really been very focused in 2018 on building out capacity. So getting the Marlborough facility up and running, adds tremendous amount of capacity for us for not only the cassette business, it allows us to build out our systems portfolio. We’ve been able to alleviate some of the bottlenecks out in Rancho for the Spectrum business by bringing basically Marlborough online. The area, where we’re continuing to look at capacity expansion is on our pre-packed columns side. We made the decision two years ago to go and build out seven production suites. That was a smart move, because we’re seeing a fairly significant uptick in demand for OPUS products. We’ve also pulled the – made the decision at the end of last year that we’re building out the Ravensburg facility for large scale OPUS. So by the end of this year, we’ll have a large-scale OPUS manufacturing in Europe, which will really help to serve our European customers. So across the board, I think, we’re in good shape on capacity. I think the pieces that we really have to look at right now is, just the manpower piece. So in some – for some product lines, we’ll be adding things like second shift. But it’s more a people thing than it is needing more space to build products. So hopefully that gives you a good overview of where we are in capacity. And I’ll turn it to Jon to talk about gross margins.

Sure. Hi, Julia. On gross margin, we finished the year at 56.1%, which represented about four-tenths of a point of improvement versus 2017, and as we’ve guided into 2018, regarding in the 56% to 57% range. And so we think we’ll be able to inch upward a bit from 2018 into more towards the middle of that range this year. The key drivers that we see internally are really the volume leverage that we’re seeing. Obviously, continued work in our OPUS mix and the resins column mix there, continued leverage of our global sourcing programs, we’re seeing reduced costs. And then lean initiatives as one of them, Tony mentioned was, bringing in the second shift to get more volume through our existing facilities. So those are some of the improvement opportunities that we’re working. As an offset, we’re also seeing that, obviously, when we take Marlborough live here in Q1, we’ll start having the depreciation effect on our business. And so that’ll be a partial offset to our improvement opportunities that we’re working on. I think overall, as you look in our longer range goal is 60%. We believe through the work that we’re doing internally plus additional M&A activities long-term that we have the opportunity to still continue to work towards that 60% margin range.

Great. Thanks. That’s helpful and congrats on quarter.

Thank you.

The next question will come from Dan Arias of Citigroup. Please go ahead.

Hi. Good morning. Thanks guys. Tony, gene therapy, it sounds like it’s kind of picking up a bit in terms of importance these days. Can you just talk about the ramp there and the expectations that you might have for 2019 and 2020. I mean, obviously, that’s a nascent field, but there are a bunch of interesting things going on. It sounds like you’re tapping into at least some of that. So I’m just curious about your level of enthusiasm there for the near term or the midterm.

Yes, we’re really enthusiastic about it, Dan. And part of the reason is obviously, here in the northeast, there was a quite a concentration of gene therapy companies. When we look at our portfolio and especially, as we began to pay a lot more attention to gene therapy over the last, say 12 to 18 months, we are seeing demand for our pre-packed columns. We’re seeing demand for flat sheet cassettes. We’re seeing demand for our hollow fiber cartridges and our cross-flow system. So a significant portion of our portfolio of products can be applied right into the workflow. A lot of while we’re working on is on the virus side. And so we have a really good – I think good traction that many of the top accounts in the world of gene therapy and we expect that it’ll be a good contributor to overall revenue and overall revenue growth for us for the foreseeable future.

Okay. Thank you. And then maybe on Spectrum, what do you think year-two synergies look like there? I mean, I’m sure it gets a bit harder to tell, but just coming off the $2 million to $3 million that you set out to do this year and then doing $4 million, do you have a target for 2019 and do you think that it’s like a similar mix between what comes out of cross selling versus just an expanded geographic reach?

Yes. So overall, our target for this year is about $5 million to $7 million worth. We absolutely believe we’re tracking towards our original goal of $15 million to $20 million. I think when we get towards the end of this year. We’ll have a better sense of where we are going to be in that overall range. Well, we feel really good about the portfolio, the integration that the sales team has gone really well. The opportunities for sure in 2018, we saw a lot of opportunities coming out of Asia, our flat sheet cassette business really benefited from overall sort of revenue synergies and the cross selling activities. I think, you’re right, it does become a little bit more challenging as we sort of add more salespeople and to integrate the teams. But when you look at the overall Spectrum portfolio and the types of applications that the products are used in today, I think we feel really bullish about the business and our ability to hit the revenue synergy targets.

And Dan, that $5 million to $7 million is baked into our 20% to 25% filtration growth number for 2019.

Yes. Okay. Thank you, Jon. Maybe if I could just one more. Tony, you’ve been pretty upfront about wanting to build out the portfolio further and Jon touched on M&A. How are you thinking about M&A opportunities in 2019 and where do you think you might be most likely to see in addition?

Yes. So overall, obviously, our blueprint’s for how we’ve gotten to where we are today is combination of organic growth, internal innovation and M&A. And that hasn’t changed. We’re clearly in 2018, active in the M&A front, looking at a potential targets. When the right target comes along, obviously, we feel like we’re in a good position to execute on that. We feel that the overall, strengths that we’re seeing in filtration and chromatography, that’s probably going to be the focus areas for us going forward. So, expect over the next few years, we’re going to continue to be active on the M&A front.

Okay. Thanks a lot guys.

Thanks, Dan.

The next question will come from Andrew Jones of Stephens Inc. Please go ahead.

Thanks. Good morning, guys. Tony, maybe could you expand on what exactly the field operation and field service team additions, what they’re doing kind of benefit to the customer and is there potential there from those guys to impact the top line?

Yes. So on the field service, so two types groups, one is the field service team. The other one is the field applications team. The applications team really assists the sales team in terms of doing demos and really working very closely with the customer, as they implement any of our technologies. And for the most part there, on the filtration side. The service business is something that we’ve been focused on for the last couple of years. We’ve really built out that team, initially, they had focused on ATF, as the really the main product line where we were offering service and service contracts on. But with the acquisition of spectrum, what we’ve been doing over the last, say 12 to 15 months is really looking at the spectrum portfolio and putting together service plans, especially around their bench to process scale and production scale, TFF systems. So we think that it’s still small in the grand scheme of things. It’s low millions of dollars in terms of revenue that’s coming in from service, but it’s growing and it’s growing rapidly and we think it’s an important sort of leg on the stool for us to continue to build out. Because there is demand from our customers and as you sell more systems and products, whether it’s ATF or it’s TFDF or it’s characterize or it’s the large-scale TFF systems that services are required and it’s something that we need to continue to focus on.

Okay. And then Tony, you called out OPUS and getting into a key commercial process, what is that tell us in terms of how we should be thinking about the opportunity for OPUS? Previously, we kind of thought it was more limited to maybe small or midsize processes. Is this a signal that maybe we’re moving upscale a little bit?

Yes, I think the way to look at it is, we’ve really rounded out the portfolio by bringing the OPUS 80R to market. And what that has done has really opened up opportunities probably outside monoclonal antibodies to get into commercial processes. Because when you think about recombinant proteins, some vaccines, basically, drugs that are manufactured at a smaller scale, the 60 centimeter, 80 centimeter columns are very appropriate for late-stage and commercial manufacturing. So we’re definitely seeing a benefit from that. I think, I’ve said previously that, one of the real advantages of getting OPUS 80 out was customers now see that we have the complete portfolio. So people who were on the fence about using OPUS now have a path forward to getting to the commercial or at least late-stage. And I think we’re benefiting from that. I think the other thing we’re benefiting on the OPUS side is, is honestly the integration of our sales force. And one of the things, we did in Q4, Andrew was, we started to bring on a couple of specialists. We have specialists in filtration, up until really Q4. We hadn’t really put specialists in the field or pre-packed columns. We’re doing that now with the focus on the large Pharma customers. We think that’s going to payoff for us over the next few years.

And then last one for me, you call that ATF is going platform with a few key accounts. Can you maybe give us a little more color on where in the process it’s being used, is it more disposable that it’s getting the attraction there? Any color would be useful?

I think, it’s a bit of both, right? Because, our single-use ATF represents about 25% now for ATF sales, so 75% is still the stainless steel portfolio. Clearly, we have customers and had customers now for the last half dozen years that are using ATF in late-stage commercial processes. So we continue to see very good traction with that installed base. And so as those customers have put ATF into commercial processes and other processes are coming through they’ve put ATF into those manufacturing workflows as well. What’s happened, I think over the last 18 months is really the benefit of getting the single-use product out. So customers who were had sort of stayed away from using ATF technology because, they didn’t have an autoclave or they didn’t want to deal with stainless steel. We’re seeing really nice attraction on single-use. And this year, we’ll start to see our single-use products end up in late-stage clinical, potentially commercial processes. So very excited about that portfolio and really seeing 60% growth in ATF in Q4 was an a very, very positive leading indicator of what we think this technology can do on a go-forward basis.

Thanks guys.

The next question will come from Paul Knight of Janney Montgomery and Scott. Please go ahead.

Hi, Tony. Could you talk about perfusion? You mentioned it in this one of your goals. I mean, perfusion is what percent of the market today and how quickly do you think perfusion is growing as a practice in biological production?

Yes, great question. So if you go back, Paul, a few years ago, I think the split was probably 80% fed-batch, 20%, perfusion. I think over the last few years, I think most people would say, that perfusions moved up to 25% of the overall market. But what’s more important is that the technology that’s being used in perfusion is now getting applied into the 75% of the market, which is fed-batch. So we’re seeing fed-batch customers using perfusion and the seed train, which is how do you build up your – basically, your concentration of cells as you go from small bioreactors all the way up to the production bioreactor. So we’re seeing implementation of ATF and our perfusion portfolio in the seed train. So that’s really opened up the fed-batch customer base for us and then with the some of the applications work that our R&D team has done, which we refer to as high productivity harvest. That’s really allowing fed-batch customers to use perfusion principles for a few days on a fed-batch bioreactor. And again, that’s opening up more opportunities for us. So we haven’t really seen the full benefit of high productivity harvest, but we’re definitely seeing the benefit of fed-batch customers using perfusion and N-1.

Okay. And then on OPUS. I know that homebrew has been the biggest market opportunity you seem to captured more and more homebrew. How much of that market do you believe is left? Is it $200 million left, is it $150 million to $200 million? Could you kind of frame it up a bit?

Yes. I think when you look at the market, we’re probably – we haven’t really gone and rerun the calculations as we finished off 2018. But probably 40% of the market is probably using pre-packed columns today. There’s still 60% of the market that’s not. I think the big part of the market that hasn’t quite moved over into pre-packed is the large biotech, the overall biotech industry in general, large biotech, large pharma. I think as those guys begin to make that transition and we’re seeing that happening, that’s where we’re going to see the next sort of growth phase for pre-packed columns.

Okay. Thanks, Tony.

Thanks, Paul.

The next question will come from John Kreger of William Blair.

Hi. Thanks very much. Can you talk a little bit about the puts and takes to organic revenue growth. As you think about this year, you obviously ended 2018 very strong and it sounds like the order flow has started 2019 off well too. What do you expect to decelerate as you go through the year? Is it just the protein OEM business or something else?

Yes. Great question, John. So if you look at 2019, I think overall we expect that the first half of 2019 is probably going to be stronger than the second half. So a little different than what we saw last year. If you look at the three main franchises that we have filtration, chromatography and proteins, we expect that the filtration and chromatography portfolios are going to be fairly evenly split across all four quarters. And we expect that the protein’s business is going to be stronger in the first half versus the second half. So probably the only change we would see between H1 and H2 is a lighter proteins business in H2.

Great. Thank you. And then, Tony, have you baked in a contribution from any new product introductions in your thinking for 2019?

We tend to be conservative on the new product introductions. Most of what we’re looking at this year, it’s going to come out probably Q2 through the end of Q3. So there’s probably some upside from new product introductions. The challenge with new product introductions is typically, you go through a seeding phase in our industry for sort of six to 12 months. So we’re excited. I think we’ll see for sure an impact from getting our ATF controller technology out and that’s absolutely baked into our ATF and filtration numbers. But when you look at TFDF technology and you look at the lab scale to production scale systems that we’re going to bring to market in the second half of the year, we don’t – we haven’t really baked in much revenue from those products.

Great. Thank you. And then one last one. From a longer term perspective, is there a point where you think the protein business can start growing again given some of the recent partnerships or should we assume that continues to decline over time?

Yes. I think a little bit. There’s a little unknown in it, simply because we know that starting next year, GE will – can reduce the overall demand down to 50%. So depending on how fast that ramps, that’s probably going to determine a little bit about the overall growth, whether it’s positive or negative for the proteins business. So I think from looking at that business, I definitely wouldn’t have it growing. I would have it flat for now to down 5%. And I think as we finish off 2019, we’ll have a better sense of where we’re going to be in 2020 and 2021. And obviously the Purolite, the NGL-Impact A ligand and some of the other affinity ligands that we’re working on, we’ll start to hit the market. So we’ll hopefully pick up some revenue and offset some of the declines that we will obviously see from the GE relationship.

Thanks much.

The next question will come from Matt Hewitt of Craig-Hallum.

Good morning. Thank you for taking the questions.

Thanks, Matt.

First one, the TFF the systems team that you’re putting together, how long do you think it’ll take for them to I guess, to get a product or products ready for market? Is that more of a 2020 revenue event or maybe even a little longer-term? Maybe how should we think about that?

No, I think, for sure we’ll see products brought to market this year, second half of the year. Obviously not going to have a big revenue impact in 2019, but for sure in 2020. We’re completely committed to building out the systems business. If you think through what I spoke about in my prepared remarks, really important for the company to pivot away from a product centric organization to a market applications organization. That also breaks down a lot of the silos around deals that we’ve done. And we now have our organization and company focused on whether it’s perfusion or clarification or it’s purification. And we felt like it was really important to have a dedicated systems team that would serve those three other businesses and start to build out integrated systems with single-use flow path, all the things that our industry needs. And we’re doing a lot of work already on the consumable side and we think it makes a lot of sense for us to have systems wrapped around our consumables.

Okay. Makes sense. And then, I guess, a couple other questions. Number one, so you exited the year, I think you said around 72% of your business is now coming from direct. Where do you see that kind of shaking out at the end of 2019? Is there a point where you’ve kind of maxed out the direct side of things, given some of your partnerships and other relationships or is that eventually going to become closer to 100% of your business will be direct?

No, no. I think our direct business is marching towards an 80%-20% split between direct and proteins. I think that’s probably a good place for Repligen as a company. We’ve been four years ago or five years ago we were 80% OEM and 20% direct. So over the last four or five years we’ve made that transformation. And I think by the end of this year, I think you saw it in Q4 with the numbers that Jon spoke about, it was almost 80% of our revenue in Q4 was coming from direct. We expect that that’s going to be – will be in the future. We don’t expect that our proteins businesses going to go down to less than 5% of overall revenue. We expect it’s going to be in that 10% to 20% range on a go forward basis.

And I think you can expect an acceleration of a few percentage points a year as we move forward.

Okay. Okay, great. And then one last one for me. Single-use ATF, obviously you’ve seen strong demand there over the past couple of years. You’ve gone from 15% to 25%. Where do you see that exiting 2019? I think that’ll wrap it up for me. Thank you.

Yes. I think overall, single-use ATF is going to continue to add 5% to 10%. So instead of being 25% of total revenue for ATF in 2018, we’ll expect it to be in that 30% to 35% of revenue in 2019.

Great. Thank you.

Yup.

The next question will come from Steve Schwartz of First Analysis.

Good morning, everyone.

Good morning, Steve.

In Jon’s prepared remarks, you talked a bit about the step up in SG&A spending. And if I look at your 2019 guidance, it looks like operating income is going to see some leverage off the revenue growth. And even if I back out the gross margin expansion, it looks like you’ll get some leverage off of SG&A in 2019. Can you talk a little bit about what’s happening there? And the elements to that, is it strictly leverage off the personnel or other factors?

Yes, you bet. Happy to do so. Well, we finished the year with adjusted operating margin in 2018 at 20.3% for the overall company. And as we mentioned earlier, we guided to 22% to 23%. So that implies about 170 basis point expansion to get to the low end of that range. So that’s kind of come from a few different areas. First of all, we talked a little bit earlier on gross margin. We expect that we can grab a 30, 40 basis points, hopefully a gross margin this year, which will help obviously expand the overall operating margin. In addition, we do expect to continue to spend on R&D up in that 7% to 8% range. So we’re not going to really reduce significantly the R&D spend. We want to continue to grow that to bring out new innovation and new products to the market. But on the SG&A side, we’ve continued to build out the commercial teams. We’ve continued to build out field applications and field service along with our infrastructure. But some more additional leverage should come from overall as we move forward. Investments, Steve, we made last year, especially on the commercial side, I think we’re going to get a benefit in 2019 from that. So, prior to 2018, our commercial teams really worked in silos, right? Spectrum’s team focused on Spectrum products, Repligen legacy is focused on Repligen legacy products. We’ve integrated those teams. We’re definitely seeing the benefit of having one sales team. And I think that’s where we’re going to see some significant leverage this year.

Right. And I think we’re going to obviously going to continue to make disciplined investments where they make sense. And so we’re obviously focused on the long range, affects of organic growth for the company. So we’ll continue to make sure that we’re supporting that as we look forward.

Yes, certainly it looks like your op income could grow greater than 20% on a 14% organic revenue growth. So there is some nice leverage coming there in 2019. With respect to service revenue, you don’t specifically break this out, but certainly with the growth in pre-packed columns and what have you, right? Is there a discernible element of service revenue? Is it changing significantly? Is that something under the surface that maybe we should be aware of?

I don’t think so, Steve. I think most of the service revenue is definitely going to come from the filtration portfolio. There’s not a whole lot that you can offer around service, around the pre-packed column piece. Essentially the column arrives ready to be used, it just needs to get hooked up. It’s not like a filtration system, whether it’s ATF for TFF skids, where you have to do IQ, OQ, PQ service contracts on the system on an annual basis. So I think it’s going to be more filtration.

Okay. And then my last question, Tony, when you went through the five strategic focus points and you noted disruptive technology development. I understand there’s a bit of a skunk works element to this where you can’t talk in great detail about it. But if you could provide us some color on maybe the arenas where you’re seeing those opportunities and what might be there for you?

Yes. I think in general the – every R&D portfolio has a balance of derivative products and disruptive products. We think that for Repligen – we’ve been very successful as a company because we’ve been able to get high impact products launched into the marketplace, whether it’s OPUS, whether it’s ATF technology, whether it’s the hollow fiber TFF systems with the single-use flow paths. All of those have been very successful in the marketplace. So when I look at the R&D portfolio, things that I’ve put in the range of disruptive technologies, NGL-Impact A ligand is definitely a disruptive technology because of its performance. And obviously we’ll see how that plays out with the Purolite resin over the next few years. We believe that ATF controllers, even though it doesn’t sound like it’s a big deal, it is a big deal. It’s going to be really beneficial for our customers. We really like the TFDF technology that Spectrum developed over the last few years and expect to see that in the marketplace later this year. So they’re the types of examples of products that we see that will have an impact. I suppose impact in the marketplace is probably the more appropriate word than disruptive, but that’s where we’re going.

Okay. But certainly things that are close within your wheelhouse of what you’ve worked on.

Yes.

Okay, very good. Thank you for taking the questions.

Yep.

The next question will come from Edward Marks of H.C. Wainwright. Please go ahead.

Good morning. This is Edward on for Ram Selvaraju. Just a few questions here. If you look towards the gene therapy sector, I was wondering if you could highlight a couple of the most significant competitors that you’re currently seeing.

I think almost everybody in our – in the bioprocessing space is focused on gene therapy, whether it’s GE or Thermo or Sartorius or Paul or Millipore. Everybody has a portfolio of products that they feel can be used and applied into the gene therapy space. We’ve just focused on the products, we have which is really our OPUS pre-packed columns or flat sheet cassettes and our hollow fiber products. And that’s what our sales team is focusing on. And honestly, because we have very good relationships and those products have been proven in the monoclonal antibodies space. I think we’ve been able to get port that over to gene therapy in a fairly easy way. So everybody in our spaces definitely competing. And all our competitors are also focused on gene therapy. So no surprise.

Okay. And you just couple of finance questions. What percentage of the revenue base currently consists of the direct sales based products?

Yes. So, we announced that in our script in Q4, our direct products represented about 79% of our sales and for the full year 2018, our direct products represented about 72% of our total sales. And of course, as Tony mentioned earlier, our target there is 80% over the next few years.

Right. Thank you. And then, I was hoping you could provide a little additional clarification on the bridge from 2019 revenue guidance around the $225 million range up to the $400 million to $500 million range that you’ve projected by 2023.

Sure. I mean, if you look at where we are right now, we expect – we’ve always said that the company is going to grow organically a 10% to 15%. We believe we can grow at the high end of that range through increased investment in R&D and getting these high impact products into the marketplace. So we’re still very confident about that. Obviously to get to that $400 million to $500 million involves M&A. That’s how we got to – back in 2015, we set a target for the company to be between $200 million and $250 million by 2020. You can clearly see that in 2019, we’re actually hitting that range. We felt like the blueprint that got us to where we are today is the same blueprint that’s going to get us to the $400 million to $500 million by 2023. So it’ll involve the M&A.

Okay. And then a final clarifying question. Did I hear correctly that the launch timing for XCell ATF controller is going to be in 2020?

No. It will be here in 2019.

Okay. All right. Thank you very much.

And this concludes our question-and-answer session. I would now like to turn the conference back over to Tony Hunt for any closing remarks.

I’d just like to thank everybody for joining us today. Look forward to getting back on in May and bringing you up to speed on how we’re doing in Q1 first half of the year. So thank you, everyone.

The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect your lines. Have a great day.